Patent · US Active

Chemical compounds

US8697685B2 · kind B2 · utility

24Cited by
0References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 18, 2009
Grant dateApr 15, 2014
Priority date
Expiry dateJul 22, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D413/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.